Skip to Content

Join the 'Actemra' group to help and get support from people like you.

Actemra News

FDA Approves Subcutaneous Formulation of Actemra for Use in Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Posted 16 Sep 2018 by Drugs.com

South San Francisco, CA – September 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients two years of age and older. Actemra can be given alone or ...

FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis

Posted 16 May 2018 by Drugs.com

South San Francisco, CA – May 14, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients two years of age and older. Actemra can be given alone or ...

FDA Approves Genentech’s Actemra (tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome

Posted 31 Aug 2017 by Drugs.com

South San Francisco, CA – August 30, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra® (tocilizumab) intravenous injection for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in patients two years of age and ...

Tocilizumab Beats Steroids for Controlling Blood Vessel Inflammation in Study

Posted 26 Jul 2017 by Drugs.com

WEDNESDAY, July 26, 2017 – The drug tocilizumab performs better than steroids in treating the most common form of blood vessel inflammation known as giant cell arteritis, a new study has shown. The phase 3 clinical trial of 251 patients confirmed that tocilizumab (Actemra) reduced symptoms and also the need for high-dose steroid treatment for the condition. Phase 3 clinical trials represent the ...

FDA Approves Actemra (tocilizumab) Subcutaneous Injection for Giant Cell Arteritis

Posted 23 May 2017 by Drugs.com

May 22, 2017 – The U.S. Food and Drug Administration today expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis. “We expedited the development and review of this application because this drug fulfills a critical need for patients with this serious ...

Actemra Approved for Certain Blood Vessel Inflammation

Posted 22 May 2017 by Drugs.com

MONDAY, May 22, 2017 – The injected drug Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis). In a media release Monday, the FDA said this form of vasculitis mostly involves blood vessels of the head. Traditional therapy includes large doses of anti-inflammatory drugs called ...

New Treatments Helping Kids With Juvenile Arthritis

Posted 20 Jul 2016 by Drugs.com

WEDNESDAY, July 20, 2016 – New treatments for juvenile arthritis offer hope to children with the chronic autoimmune condition, doctors say. Scientists are still working to understand what causes juvenile arthritis and how to stop its progression. But, kids coping with its effects have reason to be optimistic, according to Dr. Nikolay Nikolov, a rheumatologist and clinical team leader at the U.S. ...

FDA Approves Actemra for Children with Polyarticular Juvenile Idiopathic Arthritis

Posted 30 Apr 2013 by Drugs.com

BASEL, April 30, 2013 – Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Actemra (tocilizumab) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA). The medicine can be used in children two years of age and older with active disease. Actemra can be given alone or in combination with methotrexate (MTX) in people with PJIA. PJIA is a form of ...

FDA Approves Actemra (tocilizumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)

Posted 18 Apr 2011 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 15, 2011 - Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Actemra (tocilizumab) for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients two years of age and older. Actemra can be given alone or in combination with methotrexate in patients with SJIA. ...

FDA Grants Supplemental Approval for Actemra (tocilizumab)

Posted 8 Jan 2011 by Drugs.com

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan 5, 2011 - Genentech, Inc., a member of the Roche Group, today announced that the United States (U.S.) Food and Drug Administration (FDA) has extended the Actemra (tocilizumab, RoActemra in the European Union) label to include inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical ...

Ask a Question

Further Information

Related Condition Support Groups

Giant Cell Arteritis, Rheumatoid Arthritis, Cytokine Release Syndrome, Juvenile Idiopathic Arthritis

Actemra Patient Information at Drugs.com